Market Performance - The A-share market saw a collective increase in the three major indices, with the Shanghai Composite Index rising by 1.41%, the Shenzhen Component Index by 2.17%, and the ChiNext Index by 2.98% [1] - The North China 50 Index increased by 1.36% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 22,494.73 billion yuan, an increase of about 1,037.54 billion yuan compared to the previous trading day [1] Shanxi Sector Analysis - The Shanxi sector performed steadily, with an overall increase of 0.61% and a trading volume of 120.25 billion yuan, indicating a positive market sentiment [1] - Among the 41 stocks in the Shanxi sector, 28 stocks rose, 12 fell, and 1 remained flat [1] Individual Stock Performance - Notable gainers included Jinlihua Electric and Huaxiang Co., both rising over 3%, while Dongjie Intelligent, Luhua Technology, and Huayang New Materials increased by over 2% [1] - Other stocks such as Beifang Copper Industry, Kexin Development, and Shitou Co. saw increases of over 1% [1] - Decliners included Jinkong Power and Lanyan Holdings, both dropping over 2%, while Shanxi Coking Coal and Qianyuan Pharmaceutical fell by more than 1% [1] - Several stocks, including Jinkong Coal Industry, Lu'an Environmental Energy, and Jinbo Biological, experienced milder declines, with losses contained within 1% [1]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to less than 35% [2][4]. Core Insights - The company has entered into a global strategic collaboration with Eli Lilly to accelerate the global development of innovative drugs in oncology and immunology. The company will lead the research from drug discovery to clinical concept verification in China, while Eli Lilly will have exclusive rights outside Greater China [4][5]. - The company is expected to achieve a revenue increase of 45% in 2025, with projected total product revenue of approximately RMB 11.9 billion. The fourth quarter alone is anticipated to generate around RMB 3.3 billion, reflecting a year-over-year growth of over 60% [5]. - The company has a strong pipeline with 13 commercialized oncology products, and the collaboration with Eli Lilly is expected to enhance its research capabilities and market position [5]. Financial Summary - The company is projected to achieve net profits of RMB 354 million in 2025, RMB 1.427 billion in 2026, and RMB 2.404 billion in 2027, reflecting significant year-over-year growth of 304% and 68.4% respectively [7][9]. - Earnings per share (EPS) are expected to be RMB 0.20 in 2025, RMB 0.82 in 2026, and RMB 1.39 in 2027, with corresponding price-to-earnings (P/E) ratios of 346X, 86X, and 51X [7][9]. - The total revenue is forecasted to grow from RMB 6.206 billion in 2023 to RMB 20.063 billion in 2027, indicating a robust growth trajectory [9].

Group 1 - The article discusses the performance and characteristics of various ETFs tracking the STAR Market indices, highlighting their focus on high-growth sectors such as semiconductors, medical devices, and software development [2][3] - The STAR 50 ETF tracks the STAR Market 50 Index, which consists of 50 stocks with large market capitalization and good liquidity, with over 65% of its composition in the semiconductor sector [2] - The STAR 100 ETF follows the STAR Market 100 Index, focusing on medium-sized innovative companies, with over 75% of its composition in electronics, power equipment, and pharmaceutical industries [2] - The STAR 200 ETF tracks the STAR Market 200 Index, which includes 200 smaller-cap stocks, emphasizing growth potential, with a significant portion in electronics and biomedical sectors [2] - The STAR Composite Index ETF covers the entire STAR Market, focusing on core industries like artificial intelligence and new energy, and includes all 17 primary sectors listed on the STAR Market [3] - The STAR Growth ETF tracks the STAR Market Growth Index, consisting of 50 stocks with high growth rates in revenue and net profit, with over 65% in electronics and communications sectors [3] Group 2 - As of the midday close on February 9, 2026, the STAR 50 Index increased by 2.0%, while the STAR 100 Index rose by 2.5% [2] - The STAR Composite Index saw a rise of 2.2%, and the STAR Growth Index increased by 3.0% as of the same date [3] - The rolling price-to-earnings (P/E) ratios for the STAR 50, STAR 100, STAR 200, STAR Composite, and STAR Growth indices are reported at 207.8, 162.4, 217.3, and 186.0 times, respectively [2][3]

Market Overview - The Shanghai Composite Index fell by 1.27% to close at 4065.58 points, with a weekly high of 4104.62 points [2] - The Shenzhen Component Index decreased by 2.11% to 13906.73 points, reaching a high of 14213.61 points [2] - The ChiNext Index dropped by 3.28% to 3236.46 points, with a peak of 3390.3 points [2] - In the global market, the Nasdaq Composite Index declined by 1.84%, while the Dow Jones Industrial Average rose by 2.5% and the S&P 500 fell by 0.1% [2] - In the Asia-Pacific region, the Hang Seng Index decreased by 3.02%, and the Nikkei 225 Index increased by 1.75% [2] New Stock Issuance - Three new stocks were issued last week, including: - 易思维 (688816.SH) on February 2, 2026 - 海圣医疗 (920166.BJ) on February 4, 2026 - 爱得科技 (920180.BJ) on February 2, 2026 [3] Margin Trading - The total margin trading balance in the Shanghai and Shenzhen markets was 26,549.98 billion yuan, with a financing balance of 26,383.84 billion yuan and a securities lending balance of 166.14 billion yuan [4] - The margin trading balance decreased by 514.76 billion yuan compared to the previous week [4] - The Shanghai market's margin trading balance was 13,470.36 billion yuan, down by 270.75 billion yuan, while the Shenzhen market's balance was 13,079.62 billion yuan, down by 244.01 billion yuan [4] - A total of 3,485 stocks had margin buying, with 193 stocks having buying amounts exceeding 1 billion yuan, led by 中际旭创 (179.37 billion yuan), 新易盛 (169.0 billion yuan), and 信维通信 (81.09 billion yuan) [4] Fund Issuance - One new fund was issued last week: 民生加银现金增利货币C [6] Share Buybacks - Eight companies announced share buybacks last week, with the top five by execution amount being: - 步长制药 (603858) - 金田铜业 (未提供代码) - 中炬高新 (600872) - 极米科技 (未提供代码) - 泰禾智能 (603656) [8] - The highest amounts for buybacks were in the pharmaceutical, non-ferrous metals, and food and beverage industries [8]

Economic Policies - The State Council, led by Li Qiang, emphasized the importance of promoting effective investment for stabilizing economic growth and enhancing development momentum, focusing on infrastructure, urban renewal, public services, and emerging industries [1] - The People's Bank of China and eight departments issued a notice to further prevent and manage risks related to virtual currencies, stating that virtual currencies do not have the same legal status as fiat currencies [1] Capital Market Developments - Goldman Sachs warned of potential volatility in the US stock market due to algorithmic selling, with the S&P 500 index falling below a short-term trigger point, which could lead to over $33 billion in sell-offs [4] - International asset management giants, including Point72 and BlackRock, have been actively researching A-shares, particularly in high-end manufacturing and technology innovation sectors, indicating a significant increase in foreign interest [4] - Public funds are increasingly participating in hard technology sector financing, with 12 listed companies completing financing rounds, significantly increasing the amount raised compared to the previous year [4] Industry Highlights - The Ministry of Industry and Information Technology announced the construction of national computing power interconnection nodes to enhance the standardization and efficient flow of computing resources across regions and industries [6] - The humanoid robot sector is seeing increased production expectations, with companies like Qingtian Rent launching affordable experience plans, benefiting upstream material suppliers [6] - The AI medical field is set to benefit from the release of domestic high-performance GPUs, which will enhance efficiency in medical AI applications [6] - The solid-state battery industry is focusing on collaborative innovation to drive technological breakthroughs and industrialization [6] - The National Health Commission released a draft standard for pre-prepared dishes, emphasizing food safety and excluding certain food categories from this standard [6] Company Updates - Shanshan Holdings announced a restructuring plan that could change its actual controller to the Anhui State-owned Assets Supervision and Administration Commission [7] - Yongtai Technology plans to acquire a 25% stake in Yongtai High-tech from CATL, making CATL a shareholder [7] - Yunlu Co.'s chairman has had restrictions lifted and is now able to participate in daily operations [7] - Tiancheng Automation received a notification to supply products to a leading domestic automotive company [7] - Linyang Energy's major shareholder plans to increase its stake in the company by 50 to 100 million yuan within the next 12 months [7] - Meitu Inc. expects a significant increase in net profit for 2025, projecting a growth of 60% to 66% year-on-year [7] - Zhongsheng Pharmaceutical's subsidiary has reported positive results from two Phase III clinical trials for a new influenza treatment [7]

Group 1 - The core investment themes are identified as three directions: 1) Opportunities in the AI industry revolution focusing on computing power, storage, electricity, and applications [1] - The economic recovery and market liquidity suggest a "stronger gets stronger" bull market style, with cyclical stocks likely to perform better in the latter half of the cycle [1] - The concept of odds thinking is introduced, considering the potential for style rotation and bottom reversal, particularly in sectors like food and beverage, agriculture, social services, and pharmaceuticals that have underperformed for three consecutive years but have a higher probability of outperforming in the fourth year [1] Group 2 - The progress of AI industry trends depends on breakthroughs in both AI applications and consumer adoption, emphasizing the importance of AI giants' strategies [1] - In the early stages of a bull market, funds tend to favor a few high-growth sectors, while later stages see a focus on main themes, making it harder for new funds to achieve profits [1] - Cyclical stocks are characterized by low valuations and high beta, which can lead to better performance as the fundamentals improve, attracting incremental capital [1]

Core Viewpoint - The A-share market is expected to experience a cautious sentiment ahead of the Spring Festival, with the prevailing advice from institutions being to "hold stocks during the holiday" due to historical trends indicating a higher probability of market gains post-holiday [1][3]. Market Trends - Historical data shows that the probability of market gains after the Spring Festival is significantly higher than before, with a 70% chance of an increase in the first five trading days post-holiday, and the expected gain for 2024 is projected at 4.85% [1][2]. - The market typically exhibits a pattern of "reduced volume before the holiday and increased volume afterward" [1]. Institutional Recommendations - Multiple securities firms, including Guangda Securities and Huajin Securities, suggest maintaining stock positions through the holiday, anticipating a rebound in market activity post-festival [3][4]. - Citic Securities indicates that the spring market rally is likely to continue after the holiday, despite recent adjustments, and recommends holding stocks during the holiday [5][6]. Economic and Liquidity Outlook - Economic and profit expectations are anticipated to improve during the Spring Festival, with favorable consumer data expected [4]. - Liquidity is expected to remain loose, with potential increases in net injections by the central bank and a stable level of market funds before the holiday [4]. Sector Performance - Technology growth and certain cyclical sectors are expected to outperform, supported by policy initiatives and ongoing industry trends [5][7]. - There is a potential for a rebound in sectors such as pharmaceuticals, computing, chemicals, and non-bank financials, which have historically low valuation percentiles [5][6]. Market Sentiment and Style Rotation - The market sentiment is expected to stabilize post-adjustment, with a notable rotation in style from large-cap to small-cap stocks after the holiday [6][7]. - The "Spring Festival effect" and increasing event catalysts are likely to create a favorable environment for market recovery [7].

Group 1: Resumption and Suspension of Trading - Longyun Co., Ltd. plans to acquire 58% equity of Yuheng Film Industry through share issuance, leading to stock resumption [1] - Ruili Kemi intends to issue shares to purchase 16% equity of Wuhan Kedes, resulting in stock suspension [2] - Yongtai Technology aims to acquire 25% equity of Yongtai High-tech, with Ningde Times becoming a shareholder, leading to stock suspension [3] Group 2: Mergers and Acquisitions - Jinghe Integration plans to acquire 100% equity of Jingyi Integration for 2 billion yuan; Jingyi is the construction entity for Jinghe's Phase IV project [4] - Shahe Co., Ltd. intends to purchase 70% equity of Jinghua Electronics for 274 million yuan; the target company focuses on IoT smart display controllers and LCD devices [4] - Yiwan Yichuang plans to issue shares and pay cash to acquire 100% equity of Lianshi Legend; the target company specializes in AI algorithm-based intelligent marketing services [4] - Shanshan Co., Ltd. has signed a restructuring investment agreement with its controlling shareholder and subsidiaries; if successful, the actual controller will change to the Anhui State-owned Assets Supervision and Administration Commission [4] Group 3: Equity Transfers and Increases - Dongwang Times' controlling shareholder plans to publicly solicit the transfer of 6% equity [5] - Kangtai Biological's shareholder Yuan Liping intends to transfer 2% equity to Huabao Wanying Private Fund [6] - Linyang Energy's controlling shareholder Huahong Electronics plans to increase holdings by 50 million to 100 million yuan [7] Group 4: External Investments and Daily Operations - Hu Silicon Industry plans to sign a framework contract for the procurement of 3.045 billion yuan of electronic-grade polysilicon [8] - Dongtian Micro plans to invest 400 million yuan to establish a global R&D center and manufacturing headquarters in South China, focusing on precision optical components for optical communication [8] - Zhenyu Technology intends to invest in Thailand to establish a production base with an annual output of 15 million precision transmission components [9] - Lvtong Technology's investment fund plans to invest 10 million yuan in Shenghao Optoelectronics, which specializes in optical communication chip testing equipment [10] - Xinwangda's subsidiary has reached a settlement with Weir Electric, expected to impact the net profit attributable to the parent company by 500 million to 800 million yuan in 2025 [11] - Heng Rui Pharmaceutical's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties, with no similar drugs approved for sale domestically or internationally [12] - Zhixin Co., Ltd. plans to invest 1.1 billion yuan to establish an automotive welding parts project [13] - Aisheng Co., Ltd. has received patent authorization for Maxeon BC batteries and components, with total licensing fees amounting to 1.65 billion yuan [14] - Sanfu Co., Ltd. is investing in a new project with an annual output of 200 tons (Phase I: 40 tons) of SOD and supporting solvents, with a total investment of 154 million yuan, including 125 million yuan for Phase I [14] - Gongxiao Daji is participating in the auction for 60% equity of Guotou Agricultural Products Supply Chain (Beijing), with a transfer base price of 99.7776 million yuan [15]

Upstream Sector - In the upstream cyclical products, there is a price divergence, with only gold prices rising while silver and other industrial metals have declined[1] - The PPI for coal mining and washing has improved, with a year-on-year growth of -8.9% in December, up from -11.80% in November[41] - Brent crude oil prices have decreased by 6.2% to $66.30 per barrel, while WTI crude oil prices fell by 4.7% to $62.14 per barrel[15] Midstream Sector - In the steel sector, iron ore and rebar prices have increased week-on-week, with rebar prices at 3,002 RMB per ton, up 1.6%[16] - The chemical products price index has decreased by 0.9% week-on-week, indicating a downward trend in major chemical product prices[16] - The shipping industry is experiencing a decline, with the Baltic Dry Index down by 5.6%[16] TMT Sector - The semiconductor sales cycle is on the rise, with a year-on-year growth of 22.9% in China[17] - The software industry has seen a cumulative profit growth of 7.3% year-on-year[17] - The film box office revenue in China has decreased by 69.11% year-on-year, indicating a significant drop in the media sector[17] Downstream Consumption - The price of Feitian Moutai has increased, supporting the strength of the liquor market[19] - The number of breeding sows in China has decreased by 2.9% year-on-year, indicating a decline in the agricultural sector[19] - The retail sales of consumer goods in December have shown a year-on-year decline of 0.9%[19] Financial and Real Estate Sector - The cumulative year-on-year decline in China's commercial housing sales area is 8.7%[20] - The cumulative year-on-year decline in real estate development investment is 17.2%[20] - The total trading volume in the two markets has increased, with the margin financing balance remaining high, indicating a robust brokerage environment[20]

Core Viewpoint - The ChiNext Medical Index (970082) closed at 3882.75 points, down 0.63%, with a trading volume of 14.157 billion yuan and a turnover rate of 2.13% on February 6 [1] Group 1: Index Performance - Among the index constituents, 22 stocks rose while 28 stocks fell, with Tigermed leading the gainers at 3.06% and Aier Eye Hospital leading the decliners at 3.82% [1] - The top ten constituents of the ChiNext Medical Index include Aier Eye Hospital (9.18% weight, latest price 11.07, -3.82% change) and Tigermed (8.52% weight, latest price 65.65, +3.06% change) [1] Group 2: Market Capitalization - The total market capitalization of Aier Eye Hospital is approximately 103.232 billion yuan, while Tigermed's market capitalization is around 56.526 billion yuan [1] - Other notable companies include Mindray Medical (229.746 billion yuan) and Kanglong Chemical (55.486 billion yuan) [1] Group 3: Capital Flow - The net outflow of main funds from the ChiNext Medical Index constituents totaled 604 million yuan, while retail investors saw a net inflow of 412 million yuan [1] - The detailed capital flow shows that Tigermed had a net inflow of 14.716 million yuan from main funds, while retail investors experienced a net outflow of 1.41 million yuan [2]